Arbutus Biopharma CORP Form 4 insider transactions

Robert A. Beardsley, a Director at Arbutus Biopharma Corp, was granted 78,800 stock options.

Arbutus Biopharma's Chief Financial Officer, Tuan Nguyen, received grants of 73,500 restricted stock units and options to purchase 188,400 common shares.

Arbutus Biopharma's President and CEO, Lindsay Androski, received significant equity awards including restricted stock units and stock options.

Arbutus Biopharma Director Roger Sawhney was granted 157,600 stock options with an exercise price of $3.34, vesting over three years.

Tuan Nguyen, CFO of Arbutus Biopharma, was granted a stock option for 750,000 shares at an exercise price of $3.49, vesting over four years.

Tuan Nguyen, CFO of Arbutus Biopharma, was granted stock options for 750,000 common shares on March 31, 2025, vesting over four years.

Director Anuj Hasija of Arbutus Biopharma Corp. receives stock options exercisable for 157,600 common shares.

Robert A. Beardsley, a director of Arbutus Biopharma Corp, was granted stock options to purchase 157,600 common shares.

Lindsay Androski, President and CEO of Arbutus Biopharma, was granted stock options to purchase 310,422 common shares.

J. Christopher Naftzger, General Counsel and CCO of Arbutus Biopharma, received stock options and restricted stock units (RSUs) according to a recent SEC filing.

Michael J. McElhaugh, Interim President & CEO of Arbutus Biopharma, was granted stock options and restricted stock units on February 14, 2025.

David Hastings, CFO of Arbutus Biopharma, reports the acquisition of restricted stock units and stock options.

Karen Sims, Chief Medical Officer of Arbutus Biopharma, received stock options and restricted stock units (RSUs) according to a recent SEC Form 4 filing.

David C. Hastings, CFO of Arbutus Biopharma, sold shares to cover tax obligations related to vesting restricted stock units.

Karen Sims, Chief Medical Officer of Arbutus Biopharma, sold 19,348 common shares on February 4, 2025, to satisfy tax obligations related to vesting restricted stock units.

Michael J. McElhaugh, Interim President & CEO of Arbutus Biopharma, sold 23,790 common shares on February 4, 2025, to cover tax obligations related to vesting restricted stock units.

J. Christopher Naftzger, General Counsel and CCO of Arbutus Biopharma, sold 11,333 common shares on February 4, 2025, to satisfy tax obligations related to vesting restricted stock units.

Keith S. Manchester, a director at Arbutus Biopharma Corp, executed a cashless exercise of stock options and sold a portion of the underlying shares to cover the exercise price.

Director Daniel D. Burgess of Arbutus Biopharma Corporation acquired stock options for 67,000 common shares at an exercise price of $3.28 on May 23, 2024.

Director Keith S. Manchester of Arbutus Biopharma Corp. was granted stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.

Richard C. Henriques Jr., a director of Arbutus Biopharma Corp, acquired 67,000 stock options on May 23, 2024, according to a recent SEC filing.

James R. Meyers, a director of Arbutus Biopharma Corp, acquired stock options for 67,000 common shares on May 23, 2024.

Director Melissa Rewolinski of Arbutus Biopharma Corp. was granted stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.

Director Frank Torti of Arbutus Biopharma Corp. received stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.